2020 Medicines in Development ꟷ Cancer Product Name Sponsor Indication Development Status 177-Lu-edotretide ITM Solucin neuroendocrine tumors Phase III (peptide receptor radionucleotide Munich, Germany www.itm-radiopharm.com therapy) 177-Lu-NeoB Advanced Accelerator Applications solid tumors Phase I (radioligand therapy target GRPR) Millburn, NJ www.adacap.com 177-Lu-PSMA-617 Advanced Accelerator Applications metastatic castration-resistant Phase III (targeted radioligand therapy) Millburn, NJ prostate cancer www.adacap.com 177-Lu-PSMA-R2 Advanced Accelerator Applications prostate cancer Phase I (radioligand therapy target PSMA) Millburn, NJ www.adacap.com 2X-121 Oncology Venture US metastatic breast cancer, Phase II (PARP inhibitor) Scottsdale, AZ advanced ovarian cancer www.oncologyventure.com 609A 3SBio solid tumors Phase I (anti-PD1 antibody) Shenyang, China www.3sbio.com 67Cu-SARTATE™ Clarity Pharmaceuticals neuroblastoma Phase I/II (peptide receptor radionuclide Sydney, Australia www.claritypharmaceuticals.com therapy) Medicines in Development: Cancer ǀ 2020 1 Product Name Sponsor Indication Development Status 7HP349 7 Hills Pharma solid tumors Phase I (VLA-4/LFA-1 activator) Houston, TX www.7hillspharma.com 9-ING-41 Actuate Therapeutics myelofibrosis Phase II (GSK-3β inhibitor) Fort Worth, TX www.actuatetherapeutics.com ORPHAN DRUG advanced cancers, Phase I refractory malignancies (pediatric) www.actuatetherapeutics.com A166 KLUS Pharma HER2-expressing solid tumors Phase I (antibody-drug conjugate) Cranbury, NJ www.kluspharma.com AB-106 AnHeart Therapeutics solid tumors Phase I (ROS1/NTRK inhibitor) Hangzhou, China www.anhearttherapeutics.com AB-110 Angiocrine hematologic malignancies Phase I (cell replacement) San Diego, CA www.angiocrinebiosciences.com AB122 (zimberelimab) Arcus Biosciences advanced solid tumors Phase I (PD-1 inhibitor) Hayward, CA (monotherapy and combination www.gilead.com Gilead Sciences therapy) Foster City, CA Medicines in Development: Cancer ǀ 2020 2 Product Name Sponsor Indication Development Status AB154 (domvanalimab) Arcus Biosciences 1L non-small cell lung cancer Phase II (TIGIT inhibitor) Hayward, CA (NSCLC) (combination therapy) www.gilead.cpom Gilead Sciences Foster City, CA 2L+ solid tumors (combination Phase I therapy) www.gilead.com AB-205 Angiocrine Bioscience relapsed/refractory lymphoma Phase I/II (genetically-engineered cell therapy San Diego, CA (+high dose chemotherapy and www.angiocrinebioscience.com derived from human umbilical vein autologous stem cell transplantation), tissue) leukemia, myelodysplastic syndromes (MDS) (+myeloablative allogeneic double unit umbilical cord blood transplantation) AB680 Arcus Biosciences 1L pancreatic ductal adenocarcinoma Phase I (CD73 inhibitor) Hayward, CA (combination therapy) www.gilead.com Gilead Sciences Foster City, CA AB928 (etrumadenant) Arcus Biosciences 3L colorectal cancer, 1L NSCLC, Phase II (A2A/A2B receptor antagonist) Hayward, CA pancreatic ductal adenocarcinoma www.gilead.com Gilead Sciences Foster City, CA colorectal cancer, castration-resistant Phase I prostate cancer, triple negative www.gilead.com breast cancer, NSCLC Medicines in Development: Cancer ǀ 2020 3 Product Name Sponsor Indication Development Status ABBV-011 AbbVie small cell lung cancer (SCLC) Phase I (antibody-drug conjugate) North Chicago, IL www.abbvie.com ABBV-151 AbbVie solid tumors Phase I (GARP- TGF-β1 inhibitor) North Chicago, IL www.abbvie.com ABBV-155 AbbVie hematologic malignancies, Phase I (antibody-drug conjugate) North Chicago, IL solid tumors www.abbvie.com ABBV-181 (budigalimab) AbbVie hematologic malignancies, Phase I (anti-PD1 mAb) North Chicago, IL solid tumors www.abbvie.com ABBV-184 AbbVie acute myeloid leukemia (AML), Phase I (surviving TCR/CD3 T cell engager) North Chicago, IL NSCLC www.abbvie.com ABBV-368 AbbVie solid tumors (combination therapy) Phase I (anti-OX40 mAb) North Chicago, IL www.abbvie.com ABBV-467 AbbVie hematologic malignancies Phase I (MCL1 protein inhibitor) North Chicago, IL www.abbvie.com ABBV-621 AbbVie hematologic malignancies, Phase I (TRAIL receptor agonist) North Chicago, IL solid tumors www.abbvie.com Medicines in Development: Cancer ǀ 2020 4 Product Name Sponsor Indication Development Status ABBV-744 AbbVie AML Phase I (BDII-selective BET inhibitor) North Chicago, IL www.abbvie.com inhibitor) ABBV-927 AbbVie solid tumors Phase I (anti-CD40 mAb) North Chicago, IL www.abbvie.com ABBV-CLS-579 AbbVie solid tumors Phase I North Chicago, IL www.abbvie.com Calico Life Sciences www.calicolabs.com South San Francisco, CA ABBV-CX-2029 AbbVie diffuse large B-cell lymphoma (DLBCL), Phase II (antibody-drug conjugate) North Chicago, IL esophageal cancer, head and neck www.abbvie.com CytomX Therapeutics cancer, NSCLC www.cytomx.com South San Francisco, CA abexinostat Xynomic Pharmaceuticals kidney cancer Phase III (HDAC inhibitor) Dover, DE www.xynomicpharma.com follicular lymphoma Phase II www.xynomicpharma.com AbGn-107 AltruBio gastrointestinal cancer Phase I (antibody-drug conjugate) Redwood City, CA www.altrubio.com Medicines in Development: Cancer ǀ 2020 5 Product Name Sponsor Indication Development Status abivertinib Sorrento Therapeutics NSCLC Phase III (EGFR tyrosine kinase inhibitor) San Diego, CA www.sorrentotherapeutics.com ABL001 (asciminib) Novartis 3L chronic myeloid leukemia (CML) Phase III (BCR-ABL inhibitor) East Hanover, NJ (Fast Track) www.novartis.com ABM-1310 ABM Therapeutics solid tumors Phase I (BRAF inhibitor) San Diego, CA www.abmtx.com ABP 798 AbbVie chronic lymphocytic leukemia (CLL), application submitted (rituximab biosimilar) North Chicago, IL non-Hodgkin lymphoma (NHL) www.abbvie.com Amgen www.amgen.com Thousand Oaks, CA ABSK021 Abbisko Therapeutics solid tumors Phase I (CSF-1R inhibitor) Shanghai, China www.abbisko.com ABT-165 AbbVie solid tumors Phase I (DLL4xVEGF bispecific antibody) North Chicago, IL www.abbviecom ACE1702 Acepodia solid tumors Phase I (anti-HER2 antibody conjugated Burlingame, CA www.acepodia.com human natural killer cells) Medicines in Development: Cancer ǀ 2020 6 Product Name Sponsor Indication Development Status Actimab-A (CD33) Actinium Pharmaceuticals newly-diagnosed AML (over age 60) Phase II (antibody warhead enabling [AWE] New York, NY www.actiniumpharma.com radioimmunoconjugate) ORPHAN DRUG relapsed/refractory AML Phase I (combination therapy) www.actinumpharma.com Actimab-M (CD33) Actinium Pharmaceuticals multiple myeloma Phase I (AWE radioimmunoconjugate) New York, NY www.actiniumpharma.com Actimab-MDS Actinium Pharmaceuticals MDS Phase II (AWE radioimmunoconjugate) New York, NY www.actiniumpharma.com Ad/MG1-E6E7 Turnstone Biologics HPV-associated cancers Phase I (adenovirus vaccine) New York, NY www.turnstonebio.com Ad/MG1-MAGEA3 Turnstone Biologics NSCLC (combination therapy) Phase I/II (adenovirus vaccine) New York, NY www.turnstonebio.com Ad/PNP PNP Therapeutics recurrent head and neck cancer Phase I/II (purine nucleoside phosphorylase Birmingham, AL www.pnptherapeutics.com gene therapy) adagloxad simolenin OBI Pharma triple negative breast cancer Phase III (cancer immunotherapy) San Diego, CA www.obipharma.com Medicines in Development: Cancer ǀ 2020 7 Product Name Sponsor Indication Development Status adavosertib AstraZeneca ovarian cancer, solid tumors Phase II (WEE1 inhibitor) Wilmington, DE www.astrazeneca.com Adcetris® Seagen DLBCL (combination therapy) Phase III brentuximab vedotin Bothell, WA www.seagen.com 1L Hodgkin lymphoma (combination Phase II therapy), 1L Hodgkin lymphoma, www.seagen.com peripheral T-cell lymphoma (PTCL), Hodgkin lymphoma (retreatment), PTCL (retreatment), Hodgkin lymphoma (pediatric), melanoma, NSCLC ADG106 Adagene NHL, solid tumors Phase I (anti-CD137 mAb) Suzhou, China www.adagene.com ADG116 Adagene advanced solid tumors Phase I (anti-CTLA 4 mAb)) Suzhou, China www.adagene.com ADNIC Sorrento Therapeutics hematologic malignancies, Phase II (paclitaxel) San Diego, CA solid tumors www.sorrentotherapeutics.com Ad-p53 MultiVir lymphoma, solid tumors Phase II (adenoviral p53 gene therapy) Houston, TX www.multivir.com Medicines in Development: Cancer ǀ 2020 8 Product Name Sponsor Indication Development Status Ad-p53 DCV MultiVir SCLC (combination therapy) Phase II (dendritic cell vaccine) Houston, TX www.multivir.com ADP-A2M4 Adaptimmune head and neck cancer, myxoid Phase II (MAGE A4 T cell therapy) Philadelphia, PA liposarcoma, synovial sarcoma www.adaptimmune.com ORPHAN DRUG ADP-A2M4CD8 Adaptimmune MAGE-A4 positive tumors Phase I (MAGE A4 T cell therapy) Philadelphia, PA www.adaptimmune.com ADPT01 Novartis colorectal cancer (combination Phase I East Hanover, NJ therapy) triple negative www.novartis.com breast cancer (combination therapy) Ad-RTS-hIL-12 + veledimex Ziopharm Oncology glioblastoma (+cemiplimab-rwlc) Phase II (DNA-based in vivo gene therapy) Boston, MA (Fast Track) www.ziopharm.com ORPHAN DRUG glioblastoma (monotherapy), Phase I glioblastoma (+nivolumab), www.ziopharm.com pediatric brain tumors, diffuse intrinsic pontine glioma (DIPG) ADX-2191 Aldeyra Therapeutics intraocular lymphoma Phase II (DHFR inhibitor) Lexington, MA www.aldeyra.com Medicines in Development: Cancer ǀ 2020 9 Product Name Sponsor Indication Development Status ADXS-503 Advaxis NSCLC Phase I/II (live attenuated Listeria Princeton, NJ www.advaxis.com monocytogenes (Lm)-based immunotherapy) ADXS-504 Advaxis prostate cancer Phase I (live attenuated Listeria Princeton, NJ www.advaxis.com monocytogenes (Lm)-based immunotherapy) ADXS-PSA Advaxis prostate